Even though Saxenda had already been approved for obesity treatment, the use of GLP-1 receptor agonists for weight loss really picked up steam with Ozempic, perhaps because Saxenda was a daily injection, while Ozempic was a weekly injection. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.